Indivior Appoints Vanessa Procter as EVP of Corporate Affairs, Enhancing Patient Access in OUD Treatment.

Indivior has appointed Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Procter brings 25 years of biopharmaceutical industry experience, having led successful launches and advocacy initiatives. In her new role, she will oversee Corporate Communications, Government Affairs, Policy, and Advocacy, focusing on addressing public health challenges, particularly opioid use disorder treatment.

Indivior PLC (Nasdaq / LSE: INDV) has announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Procter brings 25 years of experience in the biopharmaceutical industry, having led successful product launches and advocacy initiatives. In her new role, she will oversee Corporate Communications, Government Affairs, Policy, and Advocacy, with a focus on addressing public health challenges, particularly opioid use disorder (OUD) treatment.

Procter's appointment comes at a critical time for Indivior, which is dedicated to transforming OUD from a global human crisis into a recognized and treated chronic disease. Her extensive experience in the biopharmaceutical industry includes leading corporate and government affairs for multiple organizations. Most recently, she served as Senior Vice President of Corporate Affairs at Sage Therapeutics, where she led the successful launch of ZURZUVAE™, the first pill for postpartum depression. Prior to her time at Sage, Procter held leadership positions at Alexion Pharmaceuticals and MedImmune, and worked as a health policy advisor in the U.S. House of Representatives.

"We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to priorities and executing successful multi-stakeholder strategies that drive patient access in complex regulatory environments. We look forward to her expertise and invaluable contributions as we pursue our mission to transform the lives of people living with opioid use disorder."

Procter is also committed to addressing the public health challenge of OUD. "Public policy and community engagement are critical to address this significant public health challenge; providing the framework, funding, and systems necessary to ensure treatment in the right place and at the right time," she said. "I look forward to working with the Indivior team and deepening our engagement with the people and communities we serve to further this important work."

Indivior, headquartered in Richmond, Virginia, employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. The company's vision is to ensure that all patients around the world have access to evidence-based treatment for OUD.

References:

[1] https://www.prnewswire.com/news-releases/indivior-appoints-vanessa-procter-as-executive-vice-president-of-corporate-affairs-302499820.html
[2] https://www.stocktitan.net/news/INDV/indivior-appoints-vanessa-procter-as-executive-vice-president-of-b4e6q3oqogt1.html
[3] https://www.bio.org/policy/human-health/pain-addiction
[4] https://www.nasdaq.com/press-release/indivior-appoints-vanessa-procter-executive-vice-president-corporate-affairs-2025-07